Alnylam Finds Partner for Cholesterol Program in The Medicines Company | GenomeWeb

Alnylam Pharmaceuticals racked up another partnership this week, announcing that it has inked a global development and commercialization deal for its hypercholesterolemia program with The Medicines Company.

For Alnylam, the arrangement represents an important milestone in moving ahead with the program, which includes the phase I intravenous drug ALN-PCS02 and the preclinical subcutaneous agent ALN-PCSsc, as the company had previously disclosed that it would only advance the drug candidates in collaboration with a partner.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.